Lack of resveratrol neuroprotection in developing rats treated with kainic acid

Friedman, Linda K.; Goldstein, Burton J.; Rafiuddin, A.; Roblejo, P.; Friedman, Sílvia

doi:10.1016/j.neuroscience.2012.10.063

Cited by 16 publications

(13 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To estimate the amount of injury of surface neurons along the CA1 axis, argyrophilic, silver-stained neurons were counted under a phase contrast microscope in three consecutive 0.3-mm 2 sectors with a 40× lens objective, calibrated grid reticule (10 × 100-μm 2 boxed sectors), and manual counter as previously described [49,50]. To avoid bias, silver-stained cells were counted by three experimenters blind to the experimental conditions and then averaged.…”

Section: Argyrophilic Cell Countingmentioning

confidence: 99%

“…The extrahippocampal regions were assessed from the same sections to estimate the relative injury outside of the hippocampus. An imaginary boundary was drawn around the amygdala and piriform cortex up to the entorhinal notch (entorhinal limbic cortex, ERcx), and numbers were averaged together as one structure as described previously [49]. Briefly, microscope objectives were first calibrated to a micrometer, and counting of injured surface neurons was made with a grid reticule that was placed in steps over the entire lower quadrant that included total argyrophilic cell counts from both hemispheres.…”

Section: Argyrophilic Cell Countingmentioning

confidence: 99%

See 1 more Smart Citation

Certain secondary antiepileptic drugs can rescue hippocampal injury following a critical growth period despite poor anticonvulsant activity and cognitive deficits

Halbsgut

Fahim

Kapoor

et al. 2013

Epilepsy & Behavior

View full text Add to dashboard Cite

Section: Argyrophilic Cell Countingmentioning

confidence: 99%

Section: Argyrophilic Cell Countingmentioning

confidence: 99%

Certain secondary antiepileptic drugs can rescue hippocampal injury following a critical growth period despite poor anticonvulsant activity and cognitive deficits

Halbsgut

Fahim

Kapoor

et al. 2013

Epilepsy & Behavior

View full text Add to dashboard Cite

“…Treatment led to recovery of impairment in location memory ability [272] and spatial learning and memory ability [272], and decreased the number and rate of spontaneous seizures measured using electoencepholography [274] in epileptic rats. However, RSV did not demonstrate protective effects on juvenile epileptic rats [275].…”

Section: Effect Of Rsv On Epilepsy/seizurementioning

confidence: 78%

The pharmacology of resveratrol in animals and humans

Park

Pezzuto

2015

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Diseas

258

193

View full text Add to dashboard Cite

In addition to thousands of research papers related to resveratrol (RSV), approximately 300 review articles have been published. Earlier research tended to focus on pharmacological activities of RSV related to cardiovascular systems, inflammation, and carcinogenesis/cancer development. More recently, the horizon has been broadened by exploring the potential effect of RSV on the aging process, diabetes, neurological dysfunction, etc. Herein, we primarily focus on the in vivo pharmacological effects of RSV reported over the past 5 years (2009-2014). In addition, recent clinical intervention studies performed with resveratrol are summarized. Some discrepancies exist between in vivo studies with animals and clinical studies, or between clinical studies, which are likely due to disparate doses of RSV, experimental settings, and subject variation. Nevertheless, many positive indications have been reported with mammals, so it is reasonable to advocate for the conduct of more definitive clinical studies. Since the safety profile is pristine, an added advantage is the use of RSV as a dietary supplement. This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes.

show abstract

“…The effect on seizures was associated with neuroprotection in the hippocampus, as well as a reduction in mossy fiber sprouting [101]. These promising results were not fully confirmed in a more recent study of younger kainate-treated rats [102], so that, at present, the potential of resveratrol for disease modification in epilepsy is uncertain.…”

Section: Resveratrolmentioning

confidence: 94%

The Potential of Antiseizure Drugs and Agents that Act on Novel Molecular Targets as Antiepileptogenic Treatments

2014

View full text Add to dashboard Cite

A major goal of contemporary epilepsy research is the identification of therapies to prevent the development of recurrent seizures in individuals at risk, including those with brain injuries, infections, or neoplasms; status epilepticus; cortical dysplasias; or genetic epilepsy susceptibility. In this review we consider the evidence largely from preclinical models for the antiepileptogenic activity of a diverse range of potential therapies, including some marketed antiseizure drugs, as well as agents that act by immune and inflammatory mechanisms; reduction of oxidative stress; activation of the mammalian target of rapamycin or peroxisome proliferatoractivated receptors γ pathways; effects on factors related to thrombolysis, hematopoesis, and angiogenesis; inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reducatase; brainderived neurotrophic factor signaling; and blockade of α2 adrenergic and cannabinoid receptors. Antiepileptogenesis refers to a therapy of which the beneficial action is to reduce seizure frequency or severity outlasting the treatment period. To date, clinical trials have failed to demonstrate that antiseizure drugs have such disease-modifying activity. However, studies in animal models with levetiracetam and ethosuximide are encouraging, and clinical trials with these agents are warranted. Other promising strategies are inhibition of interleukin 1β signaling by drugs such as VX-765; modulation of sphingosine 1-phosphate signaling by drugs such as fingolimod; activation of the mammalian target of rapamycin by drugs such as rapamycin; the hormone erythropoietin; and, paradoxically, drugs such as the α2 adrenergic receptor antagonist atipamezole and the CB1 cannabinoid antagonist SR141716A (rimonabant) with proexcitatory activity. These approaches could lead to a new paradigm in epilepsy drug therapy where treatment for a limited period prevents the occurrence of spontaneous seizures, thus avoiding lifelong commitment to symptomatic treatment.

show abstract

Lack of resveratrol neuroprotection in developing rats treated with kainic acid

Cited by 16 publications

References 69 publications

Certain secondary antiepileptic drugs can rescue hippocampal injury following a critical growth period despite poor anticonvulsant activity and cognitive deficits

Certain secondary antiepileptic drugs can rescue hippocampal injury following a critical growth period despite poor anticonvulsant activity and cognitive deficits

The pharmacology of resveratrol in animals and humans

The Potential of Antiseizure Drugs and Agents that Act on Novel Molecular Targets as Antiepileptogenic Treatments

Contact Info

Product

Resources

About